New hope for transplant patients: experimental drug targets severe GVHD
NCT ID NCT07197112
First seen Oct 31, 2025 · Last updated May 05, 2026 · Updated 23 times
Summary
This study tests an experimental drug called gimacabtinib in people who have acute graft-versus-host disease (GVHD) after a stem cell transplant and whose condition did not improve with standard second-line therapy. The goal is to see if the drug can control the disease and improve survival. About 15 adults will take the drug by mouth, and doctors will check their response after 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE GRADE II-IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.